Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


Nanofilm rolls towards stock market
NTU spinout Nanofilm Technologies has seemingly filed a draft prospectus with a view of listing on the domestic Singapore Stock Exchange.
Codiak Biosciences cracks IPO code
Codiak – based on research at Gothenburg and MD Anderson Cancer Center – has succeeded in going public after previously cancelling plans.
Kronos Bio crushes IPO to raise $250m
MIT's cancer drug developer Kronos Bio floated above its range in an upsized offering and saw its shares soar in price post-IPO.
Galecto elects to target $100m in IPO
Galecto has filed to go public nine years after being founded in Sweden to commercialise research from Lund and Edinburgh universities.
Kronos Bio casts IPO range
MIT's cancer therapy developer has set terms for an offering that will raise more than $185m if it floats at the top of its range.
C4 Therapeutics blows on to public markets
Dana-Farber Cancer Institute's cancer therapy developer raised $182m in an upsized IPO where it floated above its range.
Taysha rakes in $181m from public listing
UT Southwestern-founded Taysha Gene Therapies surpassed its goal after underwriters bought additional shares.
Athira attains $204m IPO
The Washington State University neurological drug developer has gone public after issuing 12 million shares priced at $17 each.

Other News

Outset Medical pumps IPO up to $278m
OSU's kidney dialysis technology provider has added about $36m to close its initial public offering, its shares having more than doubled in price.
C4 Therapeutics sees its way to IPO filing
Small molecule drug developer C4 has fied for a $100m initial public offering, three months after the Dana-Farber Cancer Institute spinout raised a $170m round.
Codiak comes back for second IPO attempt
Exosome therapy developer Codiak Biosciences – based on research at Gothenburg and MD Anderson Cancer Center – has filed to raise up to $100m.
PMV veers toward $100m IPO
PMV Pharmaceuticals – built on foundational work at Princeton – will use some of the proceeds to complete phase 1 trials of its lead asset.
QuantaMatrix to match up $71.8m IPO
QuantaMatrix is targeting $17.80 to $22.30 per share under a regulation permitting a listing on the basis of growth and technology potential.
Taysha tilts toward public markets
UT Southwestern-linked CNS disease drug developer Taysha has filed to raise up to $100m in an IPO, just weeks after its $96m series B.

Editor's Picks

Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
Big deal: Nucana and Nightstar race to public markets
Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.
test reg